Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis.
Karen M Elias, Ainslie Mitchell, Eva Stadler et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis examined the relationship between vaccine-induced neutralising antibodies and protection from severe COVID-19 in individuals with SARS-CoV-2 infection. Analyzing data from 25 studies, it found that neutralising antibody titres were associated with a relative risk of 0.57 per 10-fold increase in GMT for progression to severe disease. The study highlights the importance of understanding immune responses in vaccine efficacy.
Key findings
- Neutralising antibody titres were associated with a relative risk of 0.57 per 10-fold increase in GMT for severe COVID-19.
- Vaccine protection against severe COVID-19 was higher than that from therapeutic passive antibody administration.
- The analysis included data from 25 clinical studies and 301 studies on neutralisation titres.
Why it matters
Understanding the role of neutralising antibodies in preventing severe COVID-19 can inform future vaccine development and strategies to enhance immune responses, which is crucial for managing the ongoing pandemic.
What to keep in mind
Neutralisation titres and clinical outcomes were measured in different studies, which may introduce variability and unmeasured confounding.